MX2022001249A - Tratamiento de tumores evasivos inmunitarios. - Google Patents

Tratamiento de tumores evasivos inmunitarios.

Info

Publication number
MX2022001249A
MX2022001249A MX2022001249A MX2022001249A MX2022001249A MX 2022001249 A MX2022001249 A MX 2022001249A MX 2022001249 A MX2022001249 A MX 2022001249A MX 2022001249 A MX2022001249 A MX 2022001249A MX 2022001249 A MX2022001249 A MX 2022001249A
Authority
MX
Mexico
Prior art keywords
tumors
treatment
immune evasive
evasive
immune
Prior art date
Application number
MX2022001249A
Other languages
English (en)
Inventor
Adam Elhofy
John Puisis
Tushar Murthy
Michael Boyne
Joseph Podojil
Original Assignee
Oncour Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncour Pharma Inc filed Critical Oncour Pharma Inc
Publication of MX2022001249A publication Critical patent/MX2022001249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

La presente descripción proporciona métodos para tratar cánceres inmunológicos evasivos usando partículas con superficie funcionalizada solas o en combinación con agente terapéutico contra el cáncer.
MX2022001249A 2019-07-31 2020-07-31 Tratamiento de tumores evasivos inmunitarios. MX2022001249A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881326P 2019-07-31 2019-07-31
US202063018026P 2020-04-30 2020-04-30
PCT/US2020/044622 WO2021022218A1 (en) 2019-07-31 2020-07-31 Treatment of immune evasive tumors

Publications (1)

Publication Number Publication Date
MX2022001249A true MX2022001249A (es) 2022-05-03

Family

ID=74230608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001249A MX2022001249A (es) 2019-07-31 2020-07-31 Tratamiento de tumores evasivos inmunitarios.

Country Status (11)

Country Link
US (1) US20220257768A1 (es)
EP (1) EP4003994A4 (es)
JP (1) JP2022542461A (es)
KR (1) KR20220054305A (es)
CN (1) CN114502557A (es)
AU (1) AU2020322046A1 (es)
BR (1) BR112022001690A2 (es)
CA (1) CA3149308A1 (es)
IL (1) IL290130A (es)
MX (1) MX2022001249A (es)
WO (1) WO2021022218A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4247419A1 (en) 2020-11-18 2023-09-27 Pionyr Immunotherapeutics, Inc. Anti-marco antibodies and uses thereof
WO2023010081A1 (en) * 2021-07-28 2023-02-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Gene signature predicting tertiary lymphoid structures containing b cells
CN114480280B (zh) * 2022-03-02 2023-09-29 中国科学院理化技术研究所 烟草花叶病毒在刺激巨噬细胞极化为m1型巨噬细胞中应用
CN115944650B (zh) * 2023-01-03 2023-11-28 青岛大学 肿瘤浸润细胞在制备抗肿瘤药物中的应用及模型构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9011913B2 (en) * 2008-04-04 2015-04-21 The Regents Of The University Of California Use of functionalized magnetic nanoparticles in cancer detection and treatment
WO2018122249A1 (en) * 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
EP3694546A1 (en) * 2018-01-30 2020-08-19 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CN112823001A (zh) * 2018-07-31 2021-05-18 onCOUR制药股份有限公司 用于治疗癌症的免疫修饰粒子
CA3113621A1 (en) * 2018-09-24 2020-04-02 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors

Also Published As

Publication number Publication date
BR112022001690A2 (pt) 2022-05-03
EP4003994A1 (en) 2022-06-01
EP4003994A4 (en) 2023-09-13
US20220257768A1 (en) 2022-08-18
JP2022542461A (ja) 2022-10-03
KR20220054305A (ko) 2022-05-02
CN114502557A (zh) 2022-05-13
CA3149308A1 (en) 2021-02-04
WO2021022218A1 (en) 2021-02-04
AU2020322046A1 (en) 2022-03-10
IL290130A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
MX2022001249A (es) Tratamiento de tumores evasivos inmunitarios.
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2021012134A (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38.
MX2017013178A (es) Terapia de combinacion para cancer.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2021007790A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
AU2018265888A1 (en) Use of anti-B7H3 antibodies for treating cancer in the central nervous system
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
PH12018500869A1 (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
WO2018102589A3 (en) Anti-hrs antibodies and combination therapies for treating cancers
JOP20210314A1 (ar) Tigit وجزيئات ربط pd-1/tigit
WO2014172532A3 (en) Methods for cancer treatment
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
WO2019027987A3 (en) COMPOSITIONS AND METHODS FOR TARGETING MASAS TO TREAT CANCERS WITH SPLICE COMPLEX MUTATIONS
CR20210310A (es) Anticuerpos antiperiostina y usos de estos